CN103893692A - Pharmaceutical composition for treating myoma of uterus - Google Patents
Pharmaceutical composition for treating myoma of uterus Download PDFInfo
- Publication number
- CN103893692A CN103893692A CN201410093413.9A CN201410093413A CN103893692A CN 103893692 A CN103893692 A CN 103893692A CN 201410093413 A CN201410093413 A CN 201410093413A CN 103893692 A CN103893692 A CN 103893692A
- Authority
- CN
- China
- Prior art keywords
- parts
- pharmaceutical composition
- treatment
- hysteromyoma
- herba
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a pharmaceutical composition for treating myoma of uterus. The pharmaceutical composition is prepared from dandelion, red peony root, ligusticum wallichii, ground beeltle, moutan bark, oldenlandia diffusa and curcuma zedoary. The dosage forms include hard capsules, tablets and granules. The invention aims to provide a medicine for treating myoma of uterus with an exact curative effect.
Description
Technical field
The invention belongs to field of medicaments, be specifically related to a kind of pharmaceutical composition for the treatment of hysteromyoma and preparation method thereof.
Background technology
Hysteromyoma is the common benign tumors of female sex organs, and women at fertile age sickness rate is about 25%.Its modal clinical symptoms is: metrorrhagia, hypogastralgia, dysmenorrhea, pressure symptom, vaginal secretions increase, anemia, even cause infertile, have a strong impact on the healthy of women and daily life work, as treatment not in time, likely change malignant tumor into.
Summary of the invention
Goal of the invention of the present invention is to provide a kind of new Chinese medicine for the treatment of hysteromyoma and preparation method thereof, to remove patient's sufferings, creates good society and economic benefit.
Drug regimen raw material of the present invention is by weight ratio: 115～155 parts of Herba Taraxacis, 90～120 parts of Radix Paeoniae Rubra, 125～160 parts of Rhizoma Chuanxiongs, 65～90 parts of Eupolyphaga Seu Steleophagas, 100～140 parts of Cortex Moutans, 200～240 parts of Herba Hedyotidis Diffusaes, 75～90 parts of Rhizoma Curcumae.
Drug regimen raw material of the present invention is by weight ratio: 140 parts of Herba Taraxacis, 100 parts of Radix Paeoniae Rubra, 150 parts of Rhizoma Chuanxiongs, 80 parts of Eupolyphaga Seu Steleophagas, 120 parts of Cortex Moutans, 230 parts of Herba Hedyotidis Diffusaes, 80 parts of Rhizoma Curcumae.
Above-mentioned raw materials is made hard capsule, tablet, granule etc. by the method for accepting on pharmaceutics, is wherein preferably granule.
The preparation method of above pharmaceutical composition is: get Herba Taraxaci, that Rhizoma Curcumae two tastes are ground into fine powder is for subsequent use; Get the remaining five tastes and decoct with water 3 times, decoct 2 hours at every turn, filter, merging filtrate, concentrating under reduced pressure becomes clear paste, adds ethanol and makes to reach 30%～60% containing alcohol amount; Cold preservation 24 hours, filters, decompression filtrate recycling ethanol, and continue to be condensed into thick paste, and mix thoroughly with above-mentioned fine powder, vacuum drying, dried cream powder is broken, adds proper auxiliary materials, makes corresponding dosage form.
Adjuvant in the present invention can be acceptable any excipient or carrier on pharmaceutics.
The present invention is on Chinese medical theory basis, through a large amount of clinical practice screening gained.Its formula is simple, onset is rapid, evident in efficacy, short treating period, be difficult for recurrence.
Herba Taraxaci: heat-clearing and toxic substances removing, eliminating carbuncle eliminating stagnation.Modern pharmacy proves, Herba Taraxaci herb is containing taraxasterol, choline, inulin and pectin, can be antibacterial, lactogenesis, antitumor, function of gallbladder promoting etc.
Radix Paeoniae Rubra: clearing away heat and cooling blood; Blood circulation promoting and blood stasis dispelling.Modern pharmacy proves, Radix Paeoniae Rubra can antithrombotic, antiplatelet aggregation, blood fat reducing, arteriosclerosis, removing oxygen-derived free radicals etc.
Rhizoma Chuanxiong: blood circulation promoting and blood stasis dispelling, wind-expelling pain-stopping.Modern pharmacy proves, Rhizoma Chuanxiong contains ferulic acid and cnidium lactone has spasmolysis, and ligustilide is that the main component of spasmolytic has inhibitory action to large intestine, dysentery (Song Nei Shi), distortion, green pus, typhoid fever, Salmonella paratyphi and vibrio cholera etc.Rhizoma Chuanxiong water logging agent (1: 3) also has inhibitory action to some pathogenic dermatophytes in vitro.Have obvious analgesic activity, sodium ferulate can reduce the lipid peroxidation that H2O2 and O2 cause, has the effect of anti-OH and malonaldehyde (MDA) haemolysis.Sodium ferulate can obviously reduce complement hemolysis, suppresses the combination of complement component 3 b (C36) and erythrocyte membrane.
Eupolyphaga Seu Steleophaga: removing blood stasis, reunion of fractured tendons and bones.Can make the high low viscosity, erythrocyte aggregation index, Rigidity of red cells index cut of viscosity, whole blood of cutting of hematocrit, whole blood all reduce, erythrocyte sedimentation rate, erythrocyte sedimentation rate constant are obviously raise.In addition also have blood fat reducing, anoxia enduring, the effect such as ease pain, resist myocardial ischemia.Dry polypide includes Palmic acid, stearic acid, linoleic acid, linolenic acid, aminoacid, volatile oil; Also contain plasminogen activator sample ingredient, alkaloid, cholesterol, and the inorganic elements such as potassium, magnesium, calcium, zinc, phosphorus.Total alkaloids has blood vessel dilating, protection heart and brain anoxias (blood) effect; Water extract energy significant prolongation bleeding time and recalcification time, obviously anticoagulant rate, has shown as antithrombotic and has formed and thrombolytic effect; Decocting liquid can regulate lipid metabolism, and atherosclerosis is had to retarding action; Extract has protective effect to the hepatic injury due to D-galactose.
Cortex Moutan: clearing away heat and cooling blood; Promoting blood circulation to remove blood stasis.Modern pharmacy proves, Cortex Moutan has the effect of antiinflammatory, antibacterial, anticoagulant, inhibition tumor, enhancing immunity.
Herba Hedyotidis Diffusae: heat-clearing and toxic substances removing, medicinal powder for relieving pain knot, promoting urination to remove dampness.Modern pharmacy proves, Cortex Moutan have strengthen immunologic function, suppress tumor, antibacterial effect.
Rhizoma Curcumae: circulation of qi promoting removing blood stasis, removing food stagnancy pain relieving.Modern pharmacy proves, Rhizoma Curcumae has antitumor, antiearly pregnancy, antibacterial, anticoagulant and antithrombotic forms, antiinflammatory action.
In order to show that medicine of the present invention has therapeutic effect to hysteromyoma, the present invention has carried out following clinical experiment.
1. data and method
1.1 object of study
60 patients with uterin leiomyoma patients, all confirm through gynecologial examination and colorful ultrasonic inspection.Before this treatment, within least 3 months, do not use hormonal medicaments, parallel examining scraped proved by pathology ametria inner membrance malignant change, is not in the mood for, the important organ disease such as brain, liver, kidney.35～53 years old age, average 45 years old.60 routine patients have the clinical manifestations such as menorrhagia in various degree, menstrual cycle shortening, menostaxis, dysmenorrhea, wherein anemia person's 18 examples.
1.2 method
1.2.1 Therapeutic Method
Treatment group 30 examples, wherein anemia patient is 10 examples, hemoglobin is minimum is 59g/L, average out to 76g/L: the granule in Application Example 1, each 3 bags, every day three times, within 1st～3 days, start to take from menstruation, serveing on 3 months is a course for the treatment of.Row pelvic cavity and gynecologial examination respectively before and after medication, colorful ultrasonic is measured the three-dimensional radial line of uterus and muscular tumor, volume calculated size.Blood drawing adopts measured by radioimmunoassay follicule-stimulating hormone (FSH) (FSH), lutropin (LH), estrogen (E
2), progesterone (P), lactotropin (PRL), androgen (T), each hormone determination batch in, batch between the equal <10% of error.During medication, monthly check blood, routine urinalysis and liver function.
Matched group 30 examples, wherein anemia patient is 8 examples: application mifepristone 10mg, within 1st～3 days, start to take from menstruation, clothes before sleeping every night, serveing on 3 months is a course for the treatment of.Row pelvic cavity and gynecologial examination respectively before and after medication, colorful ultrasonic is measured the three-dimensional radial line of uterus and muscular tumor, volume calculated size.Blood drawing adopts measured by radioimmunoassay follicule-stimulating hormone (FSH) (FSH), lutropin (LH), estrogen (E
2), progesterone (P), lactotropin (PRL), androgen (T), each hormone determination batch in, batch between the equal <10% of error.During medication, monthly check blood, routine urinalysis and liver function.
1.2.2 computing formula hysteromyoma or uterus average external volume (cm
3)=0.523 × a × b × c (note: in formula, a, b, c represent respectively the three-dimensional radial line radius of uterus or hysteromyoma)
Uterus or hysteromyoma average external volume are dwindled percentage ratio (%)=[1-(a3 × b3 × c3)/(a0 × b0 × c0)] × 100% (note: in formula, a0, b0, c0 represent respectively the three-dimensional radial line radius of the front uterus for the treatment of or hysteromyoma; A3, b3, c3 represent respectively the three-dimensional radial line radius for the treatment of uterus or hysteromyoma after 3 months).
For multiple myomata person, calculate the volume of maximum muscular tumor as representative result.1.3 statistical procedures
Adopt
represent the data of surveying, statistical procedures is carried out in row t inspection, and P<0.05 is for there being significant difference.
2 results
2.1 therapeutic effect
All there is amenorrhea 1 month time in the 30 routine patients that take medicine of the present invention, dysmenorrhea symptom fades away after taking medicine; 10 routine anemia anemias are all corrected, and Hemoglobin Value rises to 130g/L by average 76g/L.Before and after medication, uterus size and muscular tumor volume-diminished situation are in table 1.
Uterus and muscular tumor change in volume situation before and after table 1 medication (
)
As can be seen from Table 1, after taking medicine, the volume of uterus and muscular tumor obviously dwindles, and dwindles more obviously with hysteromyoma, and statistical procedures difference has significance (P<0.05).
Before and after 2.2 medications, hormone serum level changes (in table 2)
Hormone serum level situation of change before and after the medication of table 2 treatment group (
)
As can be seen from Table 2, FSH, LH, E after medication
2, P average level decline before compared with medication, especially with E
2decline obviously with P, difference all has significance (P<0.01), changes not obvious before and after PRL and T value medication.Period in a medicine routine urinalysis and liver function test are all normal.
Pharmaceutical composition of the present invention has effect of blood circulation promoting and blood stasis dispelling, hard masses softening and resolving, promoting flow of QI and blood, can be used for hysteromyoma.
Specific embodiment
Embodiment 1: Herba Taraxaci 140g, Radix Paeoniae Rubra 100g, Rhizoma Chuanxiong 150g, Eupolyphaga Seu Steleophaga 80g, Cortex Moutan 120g, Herba Hedyotidis Diffusae 230g, Rhizoma Curcumae 80g.
The preparation method of granule of the present invention: get Herba Taraxaci, that Rhizoma Curcumae two tastes are ground into fine powder is for subsequent use; Get the remaining five tastes and decoct with water 3 times, decoct 2 hours at every turn, filter, merging filtrate, concentrating under reduced pressure becomes clear paste, adds ethanol and makes to reach 30%～60% containing alcohol amount; Cold preservation 24 hours, filters, decompression filtrate recycling ethanol, and continue to be condensed into thick paste, mix thoroughly with above-mentioned fine powder, vacuum drying, dried cream powder is broken, adds amylum pregelatinisatum, sodium carboxymethyl cellulose, mixes 80 mesh sieves, adds suitable quantity of water and granulates, 60 DEG C of drying under reduced pressure, granulate, is distributed into 100 bags, to obtain final product.
Embodiment 2: Herba Taraxaci 115g, Radix Paeoniae Rubra 105g, Rhizoma Chuanxiong 145g, Eupolyphaga Seu Steleophaga 70g, Cortex Moutan 135g, Herba Hedyotidis Diffusae 215g, Rhizoma Curcumae 85g.
The preparation method of hard capsule of the present invention: get Herba Taraxaci, that Rhizoma Curcumae two tastes are ground into fine powder is for subsequent use; Get the remaining five tastes and decoct with water 3 times, decoct 2 hours at every turn, filter, merging filtrate, concentrating under reduced pressure becomes clear paste, adds ethanol and makes to reach 30%～60% containing alcohol amount; Cold preservation 24 hours, filters, decompression filtrate recycling ethanol, and continue to be condensed into thick paste, and mix thoroughly with above-mentioned fine powder, vacuum drying, dried cream powder is broken, incapsulates, and to obtain final product.
Embodiment 3: Herba Taraxaci 140g, Radix Paeoniae Rubra 100g, Rhizoma Chuanxiong 150g, Eupolyphaga Seu Steleophaga 80g, Cortex Moutan 120g, Herba Hedyotidis Diffusae 230g, Rhizoma Curcumae 80g.
The preparation method of tablet of the present invention: get Herba Taraxaci, that Rhizoma Curcumae two tastes are ground into fine powder is for subsequent use; Get the remaining five tastes and decoct with water 3 times, decoct 2 hours at every turn, filter, merging filtrate, concentrating under reduced pressure becomes clear paste, adds ethanol and makes to reach 30%～60% containing alcohol amount; Cold preservation 24 hours, filters, decompression filtrate recycling ethanol, and continue to be condensed into thick paste, and mix thoroughly with above-mentioned fine powder, vacuum drying, dried cream powder is broken, adds starch, Pulvis Talci and magnesium stearate appropriate, granulates, and in flakes, coating, to obtain final product in compacting.
Claims (6)
1. a pharmaceutical composition for the treatment of hysteromyoma, is characterized in that:
According to weight portion meter, drug regimen raw material of the present invention by weight ratio: 115～155 parts of Herba Taraxacis, 90～120 parts of Radix Paeoniae Rubra, 125～160 parts of Rhizoma Chuanxiongs, 65～90 parts of Eupolyphaga Seu Steleophagas, 100～140 parts of Cortex Moutans, 200～240 parts of Herba Hedyotidis Diffusaes, 75～90 parts of Rhizoma Curcumae.
2. a kind of pharmaceutical composition for the treatment of hysteromyoma as claimed in claim 1, is characterized in that:
According to weight portion meter, drug regimen raw material of the present invention by weight ratio: 140 parts of Herba Taraxacis, 100 parts of Radix Paeoniae Rubra, 150 parts of Rhizoma Chuanxiongs, 80 parts of Eupolyphaga Seu Steleophagas, 120 parts of Cortex Moutans, 230 parts of Herba Hedyotidis Diffusaes, 80 parts of Rhizoma Curcumae.
3. a kind of pharmaceutical composition for the treatment of hysteromyoma as claimed in claim 1, is characterized in that:
Described pharmaceutical composition is that dosage form is hard capsule, tablet, granule.
4. a kind of pharmaceutical composition for the treatment of hysteromyoma as claimed in claim 3, is characterized in that:
Described medicine composition dosage form is granule.
5. the preparation method of a kind of pharmaceutical composition for the treatment of hysteromyoma as claimed in claim 1, is characterized in that:
The method is: get Herba Taraxaci, that Rhizoma Curcumae two tastes are ground into fine powder is for subsequent use; Get the remaining five tastes and decoct with water 3 times, decoct 2 hours at every turn, filter, merging filtrate, concentrating under reduced pressure becomes clear paste, adds ethanol and makes to reach 30%～60% containing alcohol amount; Cold preservation 24 hours, filters, decompression filtrate recycling ethanol, and continue to be condensed into thick paste, and mix thoroughly with above-mentioned fine powder, vacuum drying, dried cream powder is broken, adds proper auxiliary materials, makes corresponding dosage form.
6. the preparation method of a kind of pharmaceutical composition for the treatment of gynecological inflammation as claimed in claim 5, is characterized in that:
The method is: get Herba Taraxaci 140g, that Rhizoma Curcumae 80g two tastes are ground into fine powder is for subsequent use; Get remaining five tastes Radix Paeoniae Rubra 100g, Rhizoma Chuanxiong 150g, Eupolyphaga Seu Steleophaga 80g, Cortex Moutan 120g, Herba Hedyotidis Diffusae 230g, decoct with water 3 times, decoct 2 hours at every turn, filter, merging filtrate, concentrating under reduced pressure becomes clear paste, adds ethanol and makes to reach 30%～60% containing alcohol amount; Cold preservation 24 hours, filters, decompression filtrate recycling ethanol, and continue to be condensed into thick paste, mix thoroughly with above-mentioned fine powder, vacuum drying, dried cream powder is broken, adds amylum pregelatinisatum, sodium carboxymethyl cellulose, mixes 80 mesh sieves, add suitable quantity of water and granulate, 60 DEG C of drying under reduced pressure, granulate, is distributed into 100 bags.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410093413.9A CN103893692A (en) | 2014-03-05 | 2014-03-05 | Pharmaceutical composition for treating myoma of uterus |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410093413.9A CN103893692A (en) | 2014-03-05 | 2014-03-05 | Pharmaceutical composition for treating myoma of uterus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103893692A true CN103893692A (en) | 2014-07-02 |
Family
ID=50985476
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410093413.9A Pending CN103893692A (en) | 2014-03-05 | 2014-03-05 | Pharmaceutical composition for treating myoma of uterus |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103893692A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1125613A (en) * | 1995-09-12 | 1996-07-03 | 王桂兰 | Formula for treating hysteromyoma |
| CN1418680A (en) * | 2002-11-29 | 2003-05-21 | 张慧芳 | Medicine composition for treating uterus tumour |
| CN1857677A (en) * | 2006-03-24 | 2006-11-08 | 郭建华 | Oral medicine for treating hysteromyoma |
| CN102120017A (en) * | 2011-02-24 | 2011-07-13 | 张岚 | Chinese medicinal preparation for treating uterus myoma |
-
2014
- 2014-03-05 CN CN201410093413.9A patent/CN103893692A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1125613A (en) * | 1995-09-12 | 1996-07-03 | 王桂兰 | Formula for treating hysteromyoma |
| CN1418680A (en) * | 2002-11-29 | 2003-05-21 | 张慧芳 | Medicine composition for treating uterus tumour |
| CN1857677A (en) * | 2006-03-24 | 2006-11-08 | 郭建华 | Oral medicine for treating hysteromyoma |
| CN102120017A (en) * | 2011-02-24 | 2011-07-13 | 张岚 | Chinese medicinal preparation for treating uterus myoma |
Non-Patent Citations (2)
| Title |
|---|
| 傅萍等: "中医药治疗子宫肌瘤的临床及实验研究集粹", 《中医药学刊》 * |
| 胡凤媛等: "近年来子宫肌瘤治疗进展概况", 《浙江中医杂志》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102120020B (en) | Medicinal composition for treating hyperplastic diseases of breast and hysteromyoma and preparation method thereof | |
| CN106334060B (en) | Pharmaceutical composition for treating obesity type polycystic ovarian syndrome | |
| CN103479963A (en) | Traditional Chinese medicine capsules for treating rheumatoid arthritis and preparation method thereof | |
| CN104436065A (en) | Traditional Chinese medicine for treating or preventing radiographic contrast nephropathy for imaging department and preparation method | |
| CN101537159B (en) | Traditional Chinese medicine composition and preparation method and application thereof | |
| CN105287812A (en) | Medicine composition for treating irritable bowel syndromes and application of medicine composition | |
| CN102133273B (en) | Traditional Chinese medicine lipid-lowing and catharsis capsule and preparation method thereof | |
| CN103735712A (en) | Preparation method of Chinese medicinal composition and Chinese medicinal composition prepared by using preparation method | |
| CN103027978A (en) | Medicine composition for treating traumatic injury and preparation method of medicine composition | |
| CN103585539B (en) | Traditional Chinese medicine composition for treating climacteric syndrome | |
| CN102038821B (en) | Method for preparing medicinal composition for treating dysmenorrhea | |
| CN104324316A (en) | Application of traditional Chinese medicine composition to prepare medicines treating colorectal cancer | |
| CN102614343A (en) | Medicament for treating dysmenorrhea | |
| CN103977370A (en) | Pharmaceutical composition with effect of inducing diuresis to alleviate edema | |
| CN105796620A (en) | New applications of radix notoginseng and radix notoginseng extract to preparation of medicines for treating psoriasis | |
| CN112704723A (en) | A Chinese medicinal preparation for treating dysmenorrhea and its preparation method | |
| CN105902951A (en) | Traditional Chinese medicinal compound for treating osteosarcomas on basis of chemotherapeutic drugs | |
| CN103893692A (en) | Pharmaceutical composition for treating myoma of uterus | |
| CN101590208B (en) | Medicament composition for treating rheumatoid arthritis, and preparation method thereof | |
| CN104258175A (en) | Traditional Chinese medicine for treating kidney calculi and preparation method thereof | |
| CN101590173B (en) | Application of traditional Chinese medicine composition in preparing medicine for treating hypertensive intracerebral hemorrhage | |
| CN104888153A (en) | Traditional Chinese medicine preparation for treating hepatic hemangioma and preparation method therefor | |
| CN104587300A (en) | Traditional Chinese medicine composition for treating acute leukemia and preparation method of traditional Chinese medicine composition | |
| CN103816466A (en) | Traditional Chinese medicine composition for treating chest stuffiness and pains as well as preparation and preparation method thereof | |
| CN103127358B (en) | Traditional Chinese medicine composition for treating rheumatoid arthritis and preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20140702 |
|
| RJ01 | Rejection of invention patent application after publication |